Comparative Pharmacokinetics of Sustained-Release versus Immediate-Release Melatonin Capsules in Fasting Healthy Adults: A Randomized, Open-Label, Cross-Over Study
Open Access
- 25 September 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (10) , 1248
Abstract
Background: Exogenous melatonin, a nutraceutical for maintaining a healthy sleep–wake cycle and managing sleep disorders, requires large, repeated doses due to its low bioavailability and short half-life. This necessitates the development of a sustained-release formulation with a longer half-life and sustained plasma concentration. Therefore, exogenous novel 5 mg sustained-release melatonin capsules (Melatonin-SR, test product) were formulated. Methods: This open-label cross-over study compared the pharmacokinetics (maximum concentration [Cmax], time to reach Cmax [Tmax], area under the curve [AUC], and elimination half-life [t1/2]) and the safety of Melatonin-SR with 5 mg immediate-release melatonin capsules (Melatonin-IR, reference product) after single-dose oral administration in healthy fasting adults. Results: Sixteen participants (aged 18–45 years) were randomized (1:1) to receive either Melatonin-SR or Melatonin-IR in two periods with a 7-day washout period. Melatonin-SR reported a lower Cmax (11,446.87 pg/mL) compared to Melatonin-IR (22,786.30 pg/mL). The mean Tmax of Melatonin-SR and Melatonin-IR was 1.26 h and 0.87 h, respectively. The mean t1/2 of Melatonin-SR (5.10 h) was prolonged by five-fold compared to Melatonin-IR (1.01 h). One adverse event (vomiting) was reported following the administration of the Melatonin-IR. Conclusions: Melatonin-SR resulted in higher and sustained plasma melatonin concentrations for an extended period and was well-tolerated. Hence, Melatonin-SR may be a promising nutraceutical for maintaining healthy sleep.Keywords
All Related Versions
Funding Information
- Nutriventia Limited, India
This publication has 29 references indexed in Scilit:
- Melatonina en los trastornos de sueñoNeurología, 2022
- Bioavailability of Oniria®, a Melatonin Prolonged-Release Formulation, Versus Immediate-Release Melatonin in Healthy VolunteersDrugs in R&D, 2022
- Adverse events associated with oral administration of melatonin: A critical systematic review of clinical evidenceComplementary Therapies in Medicine, 2019
- Clinical pharmacokinetics of melatonin: a systematic reviewEuropean Journal of Clinical Pharmacology, 2015
- Slow-wave sleep and the risk of type 2 diabetes in humansProceedings of the National Academy of Sciences, 2008
- Influence of cigarette smoking on melatonin levels in manEuropean Journal of Clinical Pharmacology, 2005
- Melatonin, human aging, and age-related diseasesExperimental Gerontology, 2004
- Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activityBritish Journal of Clinical Pharmacology, 2003
- Basic aspects of melatonin actionSleep Medicine Reviews, 1998
- Melatonin in HumansNew England Journal of Medicine, 1997